Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Acarix adapts pathway for German reimbursement - Submission of new dossier by the end of February 2019 | ||
By: Nasdaq / GlobeNewswire - 15 Feb 2019 | Back to overview list |
|
Press release Acarix adapts pathway for German reimbursement Acarix AB (publ) (ACARIX: FN Stockholm) today announced it will file for German reimbursement directly with the Federal Joint Committee (G-BA) for its CADScorSystem®. Previously, Acarix was aiming for full reimbursement in Germany by the end of 2019, after initial discussions with relevant associations. However, a new legislation is underway which will impact the local reimbursement process and result in delays. Acarix is now intensifying its contact with the Federal Joint Committee, G-BA, about the further pathway and has prepared a dossier for submission by the end of February, aiming for full reimbursement. Thereafter, the authorities require eight weeks to assess the dossier and give feedback on requirements and potential complementary data. "Before new legislation was being considered, we were in line with our expected timeline for a late 2019 reimbursement, but this will now be delayed. In order to keep momentum, we immediately initiated a discussion process with the G-BA and will have more information by the end of April", said Per Persson, CEO of Acarix. In parallel, Acarix has also commenced a dialogue with channels in relation to the larger German statutory sick-funds, which independently may decide about reimbursing the CADScorSystem®. As a large part of hospital expenses is funded by independent statutory sick-funds this activity could significantly increase healthcare access to the CADScorSystem®. Furthermore, private reimbursement is not affected by the above changes.
For further information, please contact: Acarix is listed on Nasdaq First North in Stockholm. This information is such that Acarix (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons above, on February 15, 2019 at 20.30 (CET). About Acarix Attachment |
||
|
||
Copyright 2019 Nasdaq / GlobeNewswire | Back to overview list |